SCHEMBL7978367

SCHEMBL7978367

NC(=O)COc1cccc(Br)c1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.58
GRM4 Q14833 1/20 0.54
MAOB P27338 3/20 0.51
ALDH1A1 P00352 4/20 0.51
KDM4E B2RXH2 2/20 0.51
LMNA P02545 1/20 0.51
MRGPRX4 Q96LA9 1/20 0.51
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
PKM P14618 1/20 0.50
MAPT P10636 3/20 0.49
KMT2A Q03164 1/20 0.49
PARP15 Q460N3 1/20 0.48
PARP14 Q460N5 1/20 0.48
PARP10 Q53GL7 1/20 0.48
PARP1 P09874 1/20 0.47
POLB P06746 1/20 0.47
GAA P10253 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29893918 1.00 HSD17B10 (0.58) HSD17B10GRM4MAOBALDH1A1KDM4E
SCHEMBL1958001 0.84 LMNA (0.64) HSD17B10GRM4MAOBALDH1A1KDM4E
SCHEMBL18332925 0.83 ALDH1A1 (0.57) MAOBALDH1A1KDM4ELMNAMRGPRX4
SCHEMBL670856 0.82 HSD17B10 (0.58) HSD17B10GRM4MAOBALDH1A1KDM4E
SCHEMBL31145073 0.82 HSD17B10 (0.58) HSD17B10GRM4MAOBALDH1A1KDM4E
SCHEMBL7941851 0.82 GRM4 (0.61) HSD17B10GRM4MAOBALDH1A1KDM4E
SCHEMBL9207274 0.82 HSD17B10 (0.55) HSD17B10GRM4MAOBALDH1A1KDM4E
SCHEMBL5699237 0.80 CYP3A4 (0.50) LMNAPARP1
SCHEMBL655613 0.80 CYP3A4 (0.56) MAOBALDH1A1KDM4ELMNA
SCHEMBL1662603 0.79 PPARG (0.44) ALDH1A1KDM4ELMNASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250296915-A1 NOVEL AMINO ACID DERIVATIVES PEPTIDREAM INC (JP) 2025-09-25 US disclosed
CN-109153655-B Novel N-acylurea derivatives and compositions comprising the same for preventing or treating cardiovascular diseases 高丽大学校产学协力团 2022-09-30 CN disclosed
US-20220194928-A1 NOVEL N-ACYLUREA DERIVATIVE AND COMPOSITION COMPRISING SAME FOR PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASE UNIV KOREA RES & BUS FOUND (KR) 2022-06-23 US disclosed
US-11306073-B2 N-acylurea derivative and composition comprising same for prevention or treatment of cardiovascular disease KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) 2022-04-19 US disclosed
US-20190119261-A1 NOVEL N-ACYLUREA DERIVATIVE AND COMPOSITION COMPRISING SAME FOR PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASE KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) 2019-04-25 US disclosed
WO-2017188551-A1 NOVEL N-ACYLUREA DERIVATIVE AND COMPOSITION COMPRISING SAME FOR PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASE 고려대학교산학협력단 2017-11-02 WO disclosed
EP-2755949-B1 FUNGICIDAL 4-SUBSTITUTED-3-{PHENYL[(HETEROCYCLYLMETHOXY)IMINO]METHYL}-1,2,4-OXADIZOL-5(4H)-ONE DERIVATIVES BAYER IP GMBH (DE) 2015-10-21 EP disclosed
US-9090600-B2 Fungicidal 4-substituted-3-{phenyl[(heterocyclylmethoxy)imino]methyl}-1,2,4-oxadizol-5(4H)-one derivatives BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-07-28 US disclosed
US-20140349848-A1 FUNGICIDAL 4-SUBSTITUTED-3--1,2,4-OXADIZOL-5(4H)-ONE DERIVATIVES BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-11-27 US disclosed
EP-2755949-A1 FUNGICIDAL 4-SUBSTITUTED-3-{PHENYL[(HETEROCYCLYLMETHOXY)IMINO]METHYL}-1,2,4-OXADIZOL-5(4H)-ONE DERIVATIVES Bayer Intellectual Property GmbH (DE) 2014-07-23 EP disclosed
WO-2013037717-A1 FUNGICIDAL 4-SUBSTITUTED-3-{PHENYL[(HETEROCYCLYLMETHOXY)IMINO]METHYL}-1,2,4-OXADIZOL-5(4H)-ONE DERIVATIVES BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-03-21 WO disclosed
US-6300352-B1 FOR THERAPY OF ASTHMA ASTRAZENECA AB (SE) 2001-10-09 US disclosed
EP-0971892-A1 NOVEL PYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Astra Pharmaceuticals Limited (GB) 2000-01-19 EP disclosed
WO-1998042670-A1 NOVEL PYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ASTRA PHARMACEUTICALS LTD. (GB) 1998-10-01 WO disclosed
EP-0341694-B1 Method for production of 3-exomethylenecepham derivatives OTSUKA KAGAKU KK (JP) 1995-09-06 EP disclosed
US-4958018-A REACTING A 3-HALOMETHYL-3-CEPHEM WITH A LEAD REDUCING AGENT OTSUKA KAGAKU KABUSHIKI KAISHA (JP) 1990-09-18 US disclosed
EP-0341694-A2 Method for production of 3-exomethylenecepham derivatives OTSUKA KAGAKU KABUSHIKI KAISHA (JP) 1989-11-15 EP disclosed
US-4329454-A Cephalosporin compounds ELI LILLY AND COMPANY (US) 1982-05-11 US disclosed
US-4144391-A REPLACING AN ACETOXY GROUP BY A SULFUR NUCLEOPHILE ELI LILLY AND COMPANY (US) 1979-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250296915-A1 NOVEL AMINO ACID DERIVATIVES DNPEP, BCAT1, ANPEP HSD17B10 4316/4885GRM4 3639/4885MAOB 4567/4885
US-20140349848-A1 FUNGICIDAL 4-SUBSTITUTED-3--1,2,4-OXADIZOL-5(4H)-ONE DERIVATIVES CYP4X1, CYP4B1, CYP4Z1 HSD17B10 1293/4885GRM4 189/4885MAOB 958/4885
US-20190119261-A1 NOVEL N-ACYLUREA DERIVATIVE AND COMPOSITION COMPRISING SAME FOR PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASE TLN1, TNNI3, PTK2 HSD17B10 3831/4885GRM4 4796/4885MAOB 3725/4885
US-20220194928-A1 NOVEL N-ACYLUREA DERIVATIVE AND COMPOSITION COMPRISING SAME FOR PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASE TLN1, TNNI3, PTK2 HSD17B10 3831/4885GRM4 4796/4885MAOB 3725/4885
US-11306073-B2 N-acylurea derivative and composition comprising same for prevention or treatment of cardiovascular disease TLN1, PTK2, TNNI3 HSD17B10 3777/4885GRM4 4810/4885MAOB 3438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.